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A B S T R A C T   
When tumor cells are killed by targeted therapy, radiotherapy, or chemotherapy, they trigger their primary 
tumor by releasing pro-inflammatory cytokines. Microenvironmental interactions can also promote tumor het-
erogeneity and development. In this line, several immune cells within the tumor microenvironment, including 
macrophages, dendritic cells, regulatory T-cells, and CD8+ and CD4+ T cells, are involved in the clearance of 
apoptotic tumor cells through a process called efferocytosis. Although the efficiency of apoptotic tumor cell 
efferocytosis is positive under physiological conditions, there are controversies regarding its usefulness in 
treatment-induced apoptotic tumor cells (ATCs). Efferocytosis can show the limitation of cytotoxic treatments, 
such as chemotherapy and radiotherapy. Since cytotoxic treatments lead to extensive cell mortality, effer-
ocytosis, and macrophage polarization toward an M2 phenotype, the immune response may get involved in 
tumor recurrence and metastasis. Tumor cells can use the anti-inflammatory effect of apoptotic tumor cell 
efferocytosis to induce an immunosuppressive condition that is tumor-tolerant. Since M2 polarization and 
efferocytosis are tumor-promoting processes, the receptors on macrophages act as potential targets for cancer 
therapy. Moreover, researchers have shown that efferocytosis-related molecules/pathways are potential targets 
for cancer therapy. These include phosphatidylserine and calreticulin, Tyro3, Axl, and Mer tyrosine kinase 
(MerTK), receptors of tyrosine kinase, indoleamine-2,3-dioxygenase 1, annexin V, CD47, TGF-β, IL-10, and 
macrophage phenotype switch are combined with conventional therapy, which can be more effective in cancer 
treatment. Thus, we set out to investigate the advantages and disadvantages of efferocytosis in treatment-induced 
apoptotic tumor cells.   
1. Introduction 
Efferocytosis, the clearance of apoptotic cells (ACs) without 
inflammatory responses, is involved in several pathways that regulate 
molecules critical to the resolution of inflammation [1–3]. Defective 
efferocytosis may result in several diseases, such as autoimmune 
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disorders and cancers [2,4–7]. While cancer treatment modalities focus 
on killing cancer cells to prevent tumor development, inducing 
apoptotic tumor cells (ATCs) can act as a double-edged sword and, in 
fact, promote tumor development [8,9]. Tumor development is regu-
lated by the crosstalk between tumor cells and other cell types within the 
microenvironment of a tumor, which contains proliferating cancer cells, 
tumor stroma, blood vessels, inflammatory cells, and several related 
tissue-type cells. Although signaling is bidirectional, the tumor micro-
environment (TME) is created and regulated by tumor cells which tailor 
the molecular and cellular events within it to their own needs. And while 
numerous immune effector cells recruitment to the tumor site to perform 
their anti-tumor activities, these abilities are diminished in response to 
cancer-derived signals. In this line, immune effector cells in the micro-
environment, such as macrophages, dendritic cells (DCs), regulatory T 
cells, and CD8+ and CD4+ T cells, are not only impaired in their 
anti-tumor activities but are co-opted to facilitate tumor development 
[10,11]. Previous studies report that losing cells in malignant disease is a 
critical component of tumor dynamics. Moreover, apoptosis is a routine 
process in high-grade malignancies, where high apoptosis indicators are 
associated with poor prognosis [12]. Alongside high apoptosis rates, 
tumors also have increased cell growth rates, a process that is frequently 
neglected but is critical in the tumor dynamics [13]. It should be noted 
that higher levels of ACs might be associated with weak prognosis by 
causatively getting involved in tumor growth [14–16]. In aggressive 
tumors, the frequency of ACs is usually low, but the rate of cell loss is 
high, indicating that AC clearance is rapid [17]. In other tumors, 
including specific categories of non-Hodgkin’s lymphoma (NHL), how-
ever, increased numbers of ACs can be detected and are mostly con-
nected to infiltrating tumor-associated macrophages (TAMs) [18]. 
Hence, it is suggested that apoptosis leads to oncogenesis via several 
pathways. These paths include: recruiting and appropriately activating 
TAMs to aid tumor development and progression, direct and indirect 
trophic effects leading to net rises in the number of tumor cells, and 
anti-inflammatory, as well as tolerogenic features, which inhibit anti--
tumor immune responses [18]. 
In previous studies, it was shown that efferocytosis might be involved 
in all these paths or at least in one of them [19–27]. Thus, we set out to 
investigate the advantages and disadvantages of treatment-induced 
ATCs. 
2. Efferocytosis: molecules and pathways 
Efferocytosis quickly clears ACs through phagocytic cells and, 
therefore, typically acts to silence immune responses and promote 
Fig. 1. The steps of efferocytosis steps in physiological and pathological conditions.  
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homeostasis [1,2,4,28,29]. This process, however, is complex and in-
volves many factors/ pathways [2], though can be broadly separated 
into 5 main steps: 1) detection through “Find-Me”/“Keep-Out” signals 
(sensing and migration toward the ACs), 2) recognition through “Eat--
Me”/“Don’t-Eat-Me” signals (binding to the ACs), 3) engulfment, 4) 
processing (digestion of the ACs and debris), and 5) anti-inflammatory 
and self-tolerance responses [2,30,31] (Fig. 1). Firstly, ACs release 
“Find-Me” signals that trigger phagocyte cell migration towards them; 
these signals consist of the nucleotides UTP and ATP, the chemokine 
fractalkine (CX3CL1), and lipids sphingosine-1-phosphate (S1P) and 
lysophosphatidylcholine (LPC). After the “Find-Me” signal has been 
received, phagocytes can identify ACs by “Eat-Me” signal ligands, such 
as phosphatidylserine (PtdSer), that are found on ACs [2]. Following 
identification, phagocytic cells, particularly macrophages, then initiate 
the engulfment and processing of the ACs, which is critical to controlling 
anti-inflammatory responses [2]. In contrast to the “Eat-Me” signal, 
overexpressing “Don’t-Find-Me” signals, such as CD31 and CD47, on live 
cells was shown to result in the inhibition of phagocytosis [32,33]. 
Unsurprisingly, tumor cells were also been found to overexpress CD47, 
serving to inhibit cancer-killing immune cells and prevent tumor cell 
recognition [34,35]. Nevertheless, there remains inadequate informa-
tion on the interactions between ATCs and macrophages, as well as on 
how these interactions affect the remaining viable tumor cell population 
and their metastatic progression. Taken together, efferocytosis has 
gained the attention of many researchers because it can alter the im-
mune response and lead to the immunosuppression of anti-tumor de-
fenses, such as by generating anti-inflammatory mediators (e.g., 
transforming growth factor-beta (TGF-β), prostaglandin E2 (PGE2), and 
interleukin-10 (IL-10)) and inhibiting pro-inflammatory cytokines (e.g., 
tumor necrosis factor (TNF)) [19,36]. 
2.1. The role of efferocytosis in cancer 
Several efferocytosis-related molecules are associated with cancer 
progression, such as CD47, Axl, MerTK, MFG-E8, PtdSer, Gas6, IL-10, 
and TGF-β [20–27], and strongly influence the activity of immune 
cells in the TME [37]. According to previous studies, chemotherapy and 
irradiation stimulate a cytokine storm in the tumor stroma, causing the 
release of tumor-promoting cytokines like IL-6 and TNF-α, as well as the 
activation of macrophages to generate pro-inflammatory mediators 
through ATCs [38–41]. While debris from dead and dying tumor cells 
can cause anti-tumor immunity [42], it can also condition the micro-
environment to promote tumor expansion [43–45]. It should be 
mentioned that the immunosuppressive activity of cytokines during 
efferocytosis can further trigger the release of additional cytokines, 
stimulating the TME, augmenting cancer metastasis, and increasing 
anti-tumor immunity evasion [46]. In this regard, it is evident that cell 
death is a common event in solid tumors during their expansion, which 
can continue even in the face of cytotoxic therapy. Clearance of dead or 
dying cells in the TME by efferocytosis, therefore, is an immunosup-
pressive phenomenon [43]. In particular, the immunosuppressive 
phenotype generated by efferocytosis in tumors is achieved via a 
harmonized series of signaling episodes, such as from several compart-
ments of the tumor milieu [43,47]. The phagocytic engulfment of ACs 
modulates cytokines, influences the degree of immune inhibition, and 
ensures inflammation is not prompted and tissues are not damaged 
[48–50]. Moreover, efferocytosis promotes a tolerogenic microenvi-
ronment by affecting the phenotype of antigen-presenting macrophages 
and DCs, leading to reduced antigen cross-presentation to T cells, 
reduced T cell clonal expansion, and decreased expansion of 
antigen-dependent anti-tumor immunity [31,37]. 
It has been shown that cytokines are related to wound healing and 
immune inhibition. In this respect, efferocytosis can prompt the release 
of wound healing and immunosuppressive cytokines, including IL-4, IL- 
10, IL-13, and TGF-β, but it suppresses IL-12 and interferon (IFN)-γ as 
pro-inflammatory cytokines [51,52]. 
Although imperfect clearance of ACs can encourage disease states, 
unimpaired efferocytosis may nevertheless lead to an increase in cancer 
incidence. Indeed, researches have shown that efferocytosis can 
contribute to the expansion of a more malignant TME and to tumor 
development [53,54]. Cytokines related to wound healing and immune 
inhibition can trigger the TME and permit resistance to anti-tumor im-
munity. Overexpressing multiple ligands and receptors has also been 
revealed to contribute to efferocytosis and tumorigenesis [52,54,55]. In 
particular, studies have shown that the Axl, Tyro-3, and MerTK re-
ceptors act as bridging factors between ACs and phagocytic cells through 
binding ligands like protein S and PtdSer growth arrest-specific gene 6 
(Gas6) which are associated with different cancer types [52,56]. Acti-
vating Axl via phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) 
and mitogen-actuated protein kinase (MAPK)/extracellular 
signal-regulated kinase (Erk) signaling pathways can aid the rapid 
growth and survival of tumor cells [52,55]. In fact, activating and/or 
overexpressing MerTK can boost oncogenic signaling pathways, such as 
the Janus kinase/ signal transducers and activators of transcription 
(JAK/STAT), Src/FAK, MAPK/ErK, and PI3K/Akt, leading to tumor cell 
survival, rapid growth, and metastasis [52,53]. MerTK expression by 
macrophages in the microenvironment may also support immune sup-
pression and tumor metastasis [52,57]. 
2.2. Efferocytosis regulation by tumor-associated macrophages 
TAMs are a common type of cell in the TME and represent a prom-
ising target for cancer therapeutics given their role in promoting cancer 
development [58,59]. The activation of macrophages can simulta-
neously influence the killing of tumor cells and the development and 
expansion of the tumor. Specifically, TAMs maintain their pro-tumor 
status through their anti-inflammatory, immunosuppressive, 
pro-angiogenic, trophic, and pro-metastatic functions [60,61]. 
Notably, the polarization of TAMs towards M2 macrophage actua-
tion states plays an important role in development, tissue homeostasis, 
and wound alleviation. M2 type macrophages can inhibit inflammatory 
responses and enhance angiogenesis and tissue remodeling [62]. The 
activation mode of M2 is contrasted by classical or M1 actuation states 
which are cytocidal and tumoricidal. The factors produced by ACs, 
specifically the “Find-Me” signal S1P and the cytokine TGF-β, stimulate 
macrophage survival and polarize macrophages towards an 
anti-inflammatory and pro-tumor activation M2 type [63,64]. Chen 
et al. indicated that the tumor-recruited M2 phenotype promotes breast 
and gastric cancer metastasis via M2 macrophage-secreted chiti-
nase-3-like protein 1 (CHI3L1) protein in-vivo [11]. Interestingly, the 
common pro-tumor properties of TAMs are also maintained by phago-
cytes actuated by interaction with ACs. Here, in phagocytes, ACs drive 
tolerogenic and anti-inflammatory immune responses with which they 
interact. Moreover, ACs may also promote growth factor generation and 
pro-angiogenic responses. It should be noted that constitutive apoptosis 
in tumor-cell sub-populations further serves a critical pro-tumor func-
tion by recruiting and activating TAMs, which go on to mediate matrix 
remodeling and increase metastasis. Of note, micro-vesicles exposing 
PtdSer generated via tumor cells have been reported to enhance meta-
static activities in-vivo [65]. Moreover, pro-tumor stromal cell pop-
ulations, such as myeloid suppressor cells, fibroblasts, and 
tumor-associated ‘N2’ neutrophils, as well as neighboring tumor cells, 
may be provided with pro-tumor signals by interacting with ATCs or 
their respective products [13,66]. 
2.3. The impact of efferocytosis on tumor radiotherapy outcomes 
In general, the key objective of radiotherapy is to kill tumor cells and 
decrease tumor size. While the direct impact that cytotoxic treatment 
has on tumor cells is one determinant of radiotherapy success, patient 
treatment outcomes are also dependent on the subsequent inherent and 
adaptive immune responses that can select for tumor cells resistant to 
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local irradiation. Of course, another critical factor is the clearance of 
dead or dying tumor cells via phagocytic cells of the inherent immune 
system. Mature DCs and macrophages that engulf, process, and present 
antigens of ATCs to adaptive immune cells are capable of stimulating, 
skewing, or suppressing adaptive immune responses [67,68]. 
2.3.1. Regulating the immune response to radiotherapy- and chemotherapy- 
induced apoptotic tumor cells 
Conventional cancer therapies heavily rely on radiotherapy and 
chemotherapy. These modalities attempt to directly eliminate tumor 
cells, but, as mentioned previously, their rate of success can depend on 
inherent and adaptive anti-tumor immune responses [69,70]. During 
these therapies, DCs require signaling by toll-like receptor (TLR)-4 and 
the respective adaptor myeloid differentiation primary response 88 
(MyD88) for effective processing and cross-presentation of the antigen 
from ATCs. Apetoh et al. indicated that TLR4 loss-of-function allele re-
lapses more rapidly following radiotherapy or chemotherapy in patients 
with breast cancer. Here, it was shown that TLR-4 and high-mobility 
group box 1 (HMGB1) play an important role in initiating immune re-
sponses against radiotherapy- and chemotherapy-produced dying tumor 
cells, likely modulating the capability of DCs to process and present the 
tumor-related antigens in-vivo [69,71]. 
2.3.2. Stimulating or inhibiting the effect of debris on tumor growth 
It was shown that treatment-generated tumor cell debris (TCDs) can 
stimulate tumor growth and possibly affect cancer treatments [72–74]. 
Additional studies have similarly reported that therapy-produced debris 
can trigger tumor development by stimulating pro-inflammatory and 
pro-tumorigenic cytokines in-vitro and in-situ grafted tumor models [75, 
76]. In effect, debris-stimulated tumor growth might be a pivotal factor 
to consider in the context of cancer treatments, like chemotherapy, 
targeted therapy, and radiation, as even in the absence of genetically 
resistant mutants, tumor cells will frequently escape cytotoxic treatment 
and exhibit more resilient phenotypes [77]. Even though tumor size is 
reduced during therapy, the continual generation of AC debris preserves 
tumor growth by promoting the release of tumor-enhancing cytokines 
by macrophages. On the other hand, however, defective efferocytosis 
and the resulting aggregation of ACs in tissues may trigger an inflam-
matory response [78] that acts in an adjuvant manner, where immu-
nogenic tumor cell death occurs secondary to the administration of 
chemotherapeutic agents, uptake of cell debris by DCs, presentation of 
antigens, and activation of adaptive immunity [79,80]. Nonetheless, 
TCDs generated via radiation, the Herpes simplex virus thymidine kin-
ase/ganciclovir system, photodynamic treatment, or radio-frequency 
ablation might suppress tumor growth with the aid of induced 
anti-tumor immunity [42,81–86]. On the other hand, quick tumor 
development has an invariable correlation with ATCs mortality due to 
the formation of undesirable conditions, including hypoxia and AC 
debris accumulation [14,15,87,88]. Hence, both natural and 
therapy-induced ACTs can lead to tumor progression [89]. 
Furthermore, there exists to some degree a conundrum in the use of 
cytotoxic therapy for non-progressive cancers, where therapy-induced 
debris might accidentally trigger the proliferation of small or dormant 
tumors [90–92]. In particular, the PtdSer “Eat-Me” has an important role 
in the debris stimulation of tumors, and when it is neutralized on ACs 
with annexin V (Anx5), which binds PtdSer with high affinity, or 
anti-PtdSer antibodies, such as Bavituximab, the therapeutic activity of 
chemotherapy is restored in debris-triggered breast and non-small-cell 
lung cancers [93–95]. Anx5 was shown to enhance the immunoge-
nicity of tumor cells and decrease tumor development by inhibiting the 
immunosuppressive effects of PtdSer [23,96–98]. In the TME, these 
materials promote anti-tumor immunity by stimulating M1 phenotype 
polarization, reducing M2-like TAMs, promoting DCs maturation and 
antigen presentation, and increasing the presence of CD8+ cytotoxic T 
cells [95,99–101]. 
2.3.3. Efferocytosis regulation by calreticulin in the tumor 
microenvironment 
Calreticulin, an endoplasmic reticulum chaperone protein, is sug-
gested to have a role in immunomodulation by glycoprotein assembly 
and secretion and Ca2+ sequestration [102–104]. An “Eat-Me” signal 
resulting from calreticulin’s translocation to the cell membrane en-
hances the efferocytosis of ACs and clearance of tumor cells [105,106]. 
Furthermore, calreticulin affects the activation of phagocytes and the 
production of cytokines [107]. The knockdown of its CALR gene is also 
associated with the inhibition of cell migration and proliferation in-vitro 
and in-vivo [108]. Through TLRs and Bruton’s tyrosine kinase (Btk), it is 
indicated that calreticulin can act as a targeted cancer therapy for 
phagocytosis, given that Btk regulates the exposure of calreticulin on the 
cell surface through TLRs [109]. Feng et al. have accordingly suggested 
that cancer therapy can be significantly enhanced by combining CD47 
blockade with TLR/Btk activation [109]. In line with this, other exper-
iments have indicated that delivering multiple immunoadjuvants 
together (e.g., TLR-7 agonists and anti-CD47 antibodies) leads to a 
greater immune response [110]. Furthermore, CD47 functionalization 
has been shown to improve the ability of drug-delivery nanoparticles to 
evade macrophages [111]. 
2.3.4. Efferocytosis regulation by macrophage metabolism mediated by 
CD47 
CD47 is a “Don’t-Eat-Me” signal that is overexpressed by many 
cancers [27]. CD47 on live cells blocks the phagocytic function of 
macrophages by binding to the signal regulatory protein α 
(SIRPα)-receptor present on the cell surface of phagocytes [34]. It has 
been shown that efferocytosis is regulated by CD47-mediated macro-
phage metabolism and that stimulation with a CpG oligodeoxynucleo-
tide, TLR-9 agonist induces changes in the central carbon metabolism of 
macrophages, enabling anti-tumor activity, such as engulfment of 
CD47+ cancer cells [24]. It is indicated that TLR9 expressed by cancer 
cells is important for tumor development by activating 
polymorphonuclear-myeloid-derived suppressor cells (MDSCs), which 
enhance the immunosuppression of T cells by signal transducer and 
activator of transcription (STAT3) in prostate cancer [112]. TLR9 ex-
hibits immunosuppressive effects by stimulating and recruiting regula-
tory T cells (Tregs) and MDSCs proliferation in the TME of pancreatic 
carcinoma [113]. However, CpG activation prompts a metabolic con-
dition, requiring the oxidation of fatty acid and the shunting of tricar-
boxylic acid cycle intermediates for lipid biosynthesis [24]. Changes in 
lipid metabolism might alter the properties of the plasma membrane in 
macrophages that promote efferocytosis [114]. It was found that the 
enhancement of membrane fluidity triggered via CpG, which depends on 
acetyl-CoA shunting for de novo lipogenesis. In line with this, membrane 
fluidity regulates phagocytic synapses with CD47-SIRPα signaling as 
well as receptor clustering [115,116]. 
2.3.5. Apoptosis and efferocytosis regulation by phosphatidylserine and 
calreticulin in the tumor microenvironment 
The constitutive apoptosis of tumor-cell populations offers an 
immunosuppressive, nonphlogistic environment that can protect ma-
lignant tissue from potent anti-tumor immune mechanisms. Hence, it 
was concluded that the targeting of molecules exposed on or produced 
by ACs, such as PtdSer, can increase tumor regression by activating the 
host anti-tumor immune response. The blockade of PtdSer triggers an 
adaptive immune response against ACs, causing autoantibody genera-
tion and anti-tumor immunity [23,117,118]. Nevertheless, the cellular 
environment of the exposed PtdSer might be necessary, since the 
exogenous labeling of tumor cells with PtdSer liposomes might lead to 
the engulfment of cells by DCs, eliciting an anti-tumor immune response 
and preventing tumor progression [119]. 
Hypoxia is a critical factor in cancer progression and is linked to 
chemotherapy and radiotherapy resistance in solid tumors [120–122]. 
Hypoxic stress results in PtdSer exposure, however, this is not a 
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guarantee that apoptosis will occur. Hypoxia is also involved in cancer 
cells immune, triggering an immunosuppressive TME through tran-
scriptional and translational regulation [123,124]. Under hypoxic 
stress, the TME also releases molecules that induce the differentiation of 
TAMs into M2 type or recruit suppressor cells derived from myeloid 
lineage [125]. However, hypoxia can also increase the immunogenicity 
of tumor cells [126]. In this case, immunogenic tumor cell death is 
prompted by increasing exposure of calreticulin on the cell surface 
following endoplasmic reticulum stress [126]. Moreover, it has been 
indicated that hypoxia-induced increase in calreticulin, although not 
CD47, enhances anticancer immunity in-vivo [126]. 
A few studies showed that PtdSer is exposed to the luminal surface of 
tumor vasculature, even when apoptosis is not evident [127,128]. The 
PtdSer-exposure can be enhanced via radiotherapy and chemotherapy, 
which might have treatment advantages in-vivo [100,129]. PtdSer can 
mediate the homeostatic interaction with ACs and their environment. 
Furthermore, PtdSer-containing liposomes can prevent anti-tumor 
cytotoxicity via macrophages [19,130]. It is, therefore, suggested that 
targeting ACs or PtdSer can provide a strong approach to unleash the 
anti-tumor potency in TAMs, for instance, with classical (M1) stimuli. In 
fact, signaling pathways that are independent of PtdSer can be actuated 
in response to ACs [13]. In this line, targeting PtdSer (e.g., BPRDP056) 
demonstrates efficacy in pre-clinical breast, pancreatic, lung, and brain 
tumor models [95,99,100,118,131]. 
2.3.6. Efferocytosis regulation by the TAM receptors Tyro3, Axl, and 
MerTK in the tumor microenvironment 
The TAM receptor tyrosine kinases Tyro3, Axl, and MerTK are 
expressed in both healthy and diseased tissues and activated by the 
binding of the bridging ligand Protein S or GAS6 with apoptotic PtdSer 
[132]. Notably, these receptors are overexpressed in cancer as onco-
genes and can be found throughout the TME, aiding in the survival of 
tumor cells, such as through anticancer therapy resistance [132,133]. 
Taken alongside their pro-oncogenic and immune-inhibiting features, 
these pathways have subsequently emerged as important avenues for 
potential cancer therapy using small molecule inhibitors [134]. These 
TAM receptors were identified as co-stimulatory molecules on human T 
cells [132]. MerTK, for example, can modulate T cell memory response 
and appears to be a late co-stimulatory molecule on T cells [135]. In this 
regard, these TAM receptors are promising therapeutic targets on TAMs. 
The TAM receptors enhance efferocytosis by macrophages, binding to 
the "Eat-Me" signal PtdSer on AC membranes via Protein S and Gas6. 
Following, macrophages are polarized towards the M2 phenotype and 
increase their secretion of immunosuppressive cytokines [58]. 
The M2 phenotype has been revealed to progress prostate cancer 
bone metastasis [136]. Administration of the chemotherapy medication 
trabectedin, however, reduced the M2 phenotype in-vivo, as well as bone 
tumor growth after PC-3 prostate cancer cell intracardiac inoculation 
[136]. Similar results were also seen from the pretreatment of PC-3 cells 
with trabectedin prior to their injection [136]. Furthermore, Crittenden 
et al. showed that MerTK is significantly upregulated by TAMs after 
radiation-induced tumor cell death. Thus, reduced MerTK, or the pre-
vention of TGF-β by SM16, an orally active TGF-beta type I receptor 
inhibitor, combined with radiation mediates post-radiation tumor 
development to a better extent than radiation alone [137]. Moreover, 
Stanford et al. indicated that MerTk and TGF-β blockade decreased 
postpartum tumor metastasis of breast cancers in-vivo [21]. 
It is also indicated that monoclonal antibodies, including GMAB1, a 
high-affinity anti-3’-isoLM1/3’,6’-isoLD1 IgG, and GMAB2, bind 
neutralized Gas6 ligand to the Axl receptor and inhibit apoptosis and 
cancer progression in pancreatic ductal adenocarcinoma [138,139]. 
Utilizing warfarin, however, to regulate the Gas6-mediated activation of 
Axl might block pancreatic ductal adenocarcinoma metastasis [140]. 
Using the small molecule inhibitors RU-301 and RU- 302 to bind to Axl 
and Gas6 may also prove to be useful [141]. 
Lastly, overexpression of Tyro3 can stimulate tumor cell 
proliferation, cancer invasion, metastasis, as well as chemotherapy 
resistance that is associated with reduced overall survival in colorectal, 
hepatocellular, and breast cancer patients [142]. 
2.3.7. Efferocytosis regulation by MER Tyrosine Kinase (MerTK), and 
indoleamine-2,3-dioxygenase 1 (IDO1) 
Efferocytosis inhibits ACs from undergoing necrosis and releasing 
their inflammatory contents after apoptosis [2,4,143]. Moreover, 
efferocytosis prevents tissue damage and maintains tissue homeostasis 
by promoting immunosuppressive cytokines increasing tolerance to 
ACs-derived antigens [2,31]. which partially tolerates cancer cells 
evading treatment-induced apoptosis with deleterious consequences 
after cytotoxic cancer treatment in the TME. It was shown that after 
HER2+ mammary tumors were treated with the cancer therapeutic 
lapatinib, efferocytosis cleared ATCs in the TME and the levels of 
immunosuppressive cytokines, as well as MDSCs and Tregs, increased 
in-vivo [144]. On the contrary, defective efferocytosis induced secondary 
necrosis of ACs and failed to increase tumor immunosuppressive cyto-
kines, MDSCs, and Tregs. It was further shown that efferocytosis triggers 
the expression of IFN-γ, stimulating indoleamine-2,3-dioxygenase (IDO) 
1 expression, an immune regulator that contributes to antigen tolerance. 
Inhibiting efferocytosis together with IDO1 reduces AC- and NC-induced 
immunosuppressive phenotypes in tumor residual disease, blocks tumor 
metastasis, and causes tumor regression in-vivo. Thus, apoptotic and 
necrotic tumor cells modulate the TME through distinct ways including 
efferocytosis and IDO1. These distinct pathways by inducing 
immune-suppressing leukocytes and cytokines can enhance tumor ’ho-
meostasis’ and development [144]. Furthermore, it is reported that 
genetic ablation of IDO Tregs leads to a defect in the tolerance to antigens 
associated with ATCs in mice [145]. 
2.3.8. Tumor therapy by targeting of Mer Proto-Oncogene, Tyrosine Kinase 
(MerTK) 
It is essential to consider the risks of blocking efferocytosis, which is a 
potential tumor treatment approach, and necrotic cell (NCs) lysis of 
dying cells, tissue injury, inflammation, and autoimmunity [21,146]. 
Another study showed that the inability of postpartum efferocytosis in 
the mammary gland can cause inflammation and scarring and interfere 
with lactation [146]. The blockage of MerTK, however, might lower the 
expression levels of wound healing cytokines, producing a condition in 
which tumor cells have a lower probability of escaping immune tar-
geting and metastasizing. Moreover, MerTK can promote the expression 
of programmed cell death ligand 1 (PD-L1), an immune checkpoint 
ligand expressed on tumor cells that antagonizes CD8+ T-cells [53,147]. 
Blockage of MerTK, therefore, might directly contribute to the stimu-
lation of anti-tumor immune invasion by reversing the immunosup-
pressive ability of the tumor cell. Together, researchers have proposed 
that multiple MerTK suppressors, such as UNC569, UNC2025, 
BMS-777607, AT9283, Neratinib/HKI-272, and UNC2881, show prom-
ise for treating cancer [148–152]. 
2.3.9. Efferocytosis regulation by complement component 1q (C1q) in the 
tumor microenvironment 
C1q is involved in immune and non-immune cell activities, such as 
the clearance of ACs, placental expansion, and sensorial synaptic 
pruning. It has been reported that C1q can encourage tumor progression 
by facilitating adhesion, proliferation, migration, angiogenesis, and 
metastasis [153,154]. In fact, C1q is highly expressed in all malignant 
pleural mesothelioma (MPM) histotypes, a rare form of cancer 
commonly linked to the exposure of asbestos [155]. When C1q is bound 
to hyaluronic acid, it can facilitate the adhesion, as well as growth and 
proliferation of mesothelioma cells (MES) by increasing ERK1/2, 
stress-activated protein kinase/c-Jun NH(2)-terminal kinase 
(SAPK/JNK), and p38 phosphorylation, without activating the comple-
ment cascade [155]. C1q is also reported to be involved in tumor im-
mune infiltration (e.g., follicular helper T cells, memory B cells, and CD8 
A. Tajbakhsh et al.                                                                                                                                                                                                                             
Biomedicine & Pharmacotherapy 140 (2021) 111776
6
T cells) in osteosarcoma and may represent a useful prognostic factor for 
predicting the metastasis and prognosis of osteosarcoma patients [156]. 
2.3.10. Efferocytosis regulation by high-mobility group box 1 (HMGB1) in 
cancer therapy 
Many proteins perform intracellular and extracellular duties that 
contribute to the recruitment of immune cells. During chronic damage 
and metabolic perturbation, such proteins can be critical to the complex 
pro-inflammatory episodes that lead to the repair of damaged tissues 
and restore organ dysfunction. It was shown that the pharmacological 
selection of the damage-associated molecular patterns (DAMPs), as 
called alarmins, can have some benefits. Nonetheless, alarmins provide 
local and systemic contributions that depend on respective post- 
translational alteration modes, differential receptor involvement, and 
other cellular influences [157,158]. HMGB1 can bind to TLRs and the 
receptor for advanced glycation end products (RAGE). Notably, the 
biological impacts of HMGB1 can depend on its level of expression and 
subcellular position. When a tumor is developing, HMGB1 has been 
described as both a pro-tumoral and anti-tumoral protein through its 
promotion or suppression of tumor growth, angiogenesis, and metastasis 
[159]. This is in line with other reports that HMGB1 possesses both 
oncogenic and tumor-inhibiting roles during the progression and treat-
ment of tumors [160]. In addition, HMGB1-mediated immunogenic cell 
mortality might contribute to the immune-mediated elimination of tu-
mors during radiotherapy or chemotherapy [69,161,162]. The release of 
dying tumor cells or exposure to DAMPs, such as ATP, heat shock pro-
teins (HSP), and HMGB1, can lead to immunogenic cell death. These 
DAMPs benefit the maturation, antigen uptake, and antigen presenta-
tion of DCs and can be used as immunological adjuvants to active 
cytotoxic T lymphocyte responses [163]. 
DAMPs polarize macrophages towards the M1 phenotype, which 
contributes to anti-tumor functions [37]. Moreover, obstructing the 
HMGB-TLR4 pathway prevents the immunogenic cell death-related 
anticancer immune response resulting from chemotherapy both in-vi-
tro and in-vivo [69,164]. In addition, when HMGB1 is released from 
necrotic cancer cells under chemotherapy treatment, it can promote 
metastasis in the remaining cancer cells in a RAGE-dependent manner 
[165]. Therefore, blockage of HMGB1-RAGE signaling enhances 
chemotherapy efficacy [166]. TLR4 in DCs is crucial to 
HMGB1-mediated immunogenic cell death and tumor clearance, while 
RAGE in cancer cells is necessary for HMGB1-mediated survival 
following chemotherapy. Even though ACs and NCs are capable of 
releasing HMGB1, HMGB1 released from ACs differ in that they can 
tolerate immunity [167]. The rapid clearance of ACs by efferocytosis 
leads to the inhibition of HMGB1 release. Furthermore, HMGB1 bound 
to T cell immunoglobulin- and mucin domain (TIM)-3 in 
tumor-associated DCs (TADCs) can be essential for the immune evasion 
of tumor cells in response to chemotherapy and vaccines, suggesting that 
there exists a balanced system between TLR4 and TIM-3 in DCs [164, 
168]. During chemotherapy, the clearance of immunogenic cell 
death-mediated tumors depends on several factors, such as tumor type, 
which can act in a tumor cell transplant model or an immunogenic 3- 
methylcholanthrene-induced fibrosarcoma model but not a spontaneous 
mammary tumor models [169]. Additionally, TLR2 in TADCs might 
mediate the regression of T cell-dependent brain tumors in anti-brain 
cancer immunotherapy [170]. 
It is widely accepted that extracellular HMGB1 serves a pro-tumor 
function given its respective chemokines, cytokines, and growth activ-
ities. On the contrary, intracellular HMGB1 plays an anti-tumor role 
because of its ability to sustain autophagy activity and genome stability 
during tumor growth. Interestingly, extracellular HMGB1 leads to 
immunogenic cell death-related anti-tumor immunity in the initial 
phase of chemotherapy but can stimulate residual tumor survival in the 
later phases of chemotherapy. Additionally, suppressing the intracel-
lular expression of HMGB1 might prevent autophagy and increase 
apoptosis by boosting the efficacy of the anticancer treatments [160, 
171]. 
2.3.11. Efferocytosis regulation by C-X-C Motif Chemokine Ligand 5 
(CXCL5) in metastatic tumor growth 
It is suggested that the expression of CXCL5, a pro-inflammatory 
cytokine, was induced through the efferocytosis of prostate tumor 
cells by macrophages via the stimulation of STAT3 and NF-κB(p65) 
signaling in-vitro [172]. Tumors triggered by apoptosis show higher 
expression of CXCL5, and CXCL5 deficiency reduces tumor develop-
ment. It has been further indicated that peripheral blood monocytes are 
more efferocytotic in patients with prostate cancer who have bone 
metastasis in-vivo. Moreover, CXCL5 serum levels are higher in patients 
with metastatic prostate cancer. It, therefore, seems that the effer-
ocytosis of ATCs by myeloid phagocytes prompts inflammation medi-
ated by CXCL5 and tumor growth in the bone [172]. The CXCL5/ CXCL8 
cluster might serve as a prognostic signal for hepatocellular carcinoma 
and a possible biomarker to direct the identification of hepatocellular 
carcinoma patients for immunotherapy using immune checkpoint in-
hibitors [173]. 
2.3.12. Efferocytosis regulation by the SIAH2-NRF1 axis in mitochondria 
It is indicated that Siah E3 ubiquitin protein ligase 2-(SIAH2)- nu-
clear respiratory factor 1 (NRF1) axis remodels the TME by controlling 
several processes, such as tumor mitochondrial activity, the polarization 
of TAMs, and cell death [174,175]. These events can lead to tumor 
maintenance, as well as development. The expression of 
nuclear-encoded mitochondrial genes (NEMGs) and mitochondrial ac-
tivity are decreased in hypoxic tumors [176]. In line with this, 
hypoxia-activated SIAH2 downregulates the expression of NEMGs, such 
as pyruvate dehydrogenase beta, by degrading NRF1, resulting in an 
enhanced pro-tumor immune response. Reducing NRF1 degradation by 
hypoxia prevents the polarization of TAMs. Moreover, NRF1 degrada-
tion stimulates tumor cells to become more responsive to apoptosis in a 
Fas-associated protein with a death domain (FADD)-dependent manner, 
leading to secondary necrosis due to the impairment of efferocytosis 
[174]. The accumulation of NRF1 increases FADD-dependent apoptosis 
and prevents efferocytosis in-vivo [174]. 
2.3.13. Efferocytosis regulation by reactive oxygen species (ROS) 
JS-K is a nitric oxide donor, which blocks tumor cell proliferation and 
stimulates AC death in-vivo. In addition to inhibiting the proliferation of 
gastric cancer cells in-vitro and in-vivo, JS-K also stimulates mitochon-
drial apoptosis. In this line, JS-K might target the mitochondrial respi-
ratory chain (MRC) complexes I and IV and antioxidant enzymes to exert 
reactive oxygen species (ROS)-dependent anti-tumor activity. JS-K 
triggers an accumulation of ROS, and ROS clearance via antioxidant 
reagents reverses JS-K-stimulated toxicity in-vitro and ex-vivo. It is 
indicated that ROS mediates the anti-tumor effects of JS-K in gastric 
cancer, in which JS-K down-regulates MRC complex I and IV proteins, 
leading to decreased MRC complex I and IV function and ROS genera-
tion. JS-K inhibits the expression of antioxidant enzymes such as copper- 
zinc-containing superoxide dismutase (Cu,Zn-SOD) and catalase, lead-
ing to the reduction of antioxidant enzyme activity and the suppression 
of ROS clearance [177]. Generating ROS via oxidative stress also results 
in the externalization of PtdSer on the cell surface [178,179]. 
Thus, the inhibition of extracellular ROS (e.g., by nanoscavenger) is a 
promising strategy to improve cancer immunotherapy efficacy [180]. 
2.3.14. Efferocytosis regulation by epithelial-mesenchymal transition 
(EMT) 
The epithelial-mesenchymal transition (EMT) as a biological process 
occurs under both physiological and pathological conditions. Under 
pathological conditions, like cancer, EMT is induced by different path-
ways. In this case, the mesenchymal properties of epithelial cells result 
in enhanced motility and metastasis [181–183]. Cytokines involved in 
anti-tumor immune inhibition within the TME are also known for their 
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respective contributions to the EMT of tumor cells [50]. TGF-β is the 
most important EMT inducer and acts by binding to receptor tyrosine 
kinases. The TGF-β pathway cooperates in regulating repressor genes 
with Zeb1, Snail, Slug, and Twist during EMT initiation. It is executed by 
repressing E-cadherin expression which actuates the cascade of this 
cellular phenomenon [184,185]. In particular, switching E-cadherin to 
N-cadherin leads to the alteration of vimentin and keratin cell surface 
proteins, causing the cell shape to change from epithelial to mesen-
chymal [186,187]. 
Based on previous studies, conditioned medium extracted from 
macrophages subjected to ACs suppresses TGF-β1-induced EMT, such as 
by causing a loss of E-cadherin, synthesizing N-cadherin and α-smooth 
muscle actin, and stimulating EMT-actuating transcription agents, such 
as Zeb1/2, Snail1/2, and Twist1 in lung cancer cells in-vitro [188,189]. 
In fact, the activity of apoptotic cancer cell-induced peroxisome 
proliferator-activated receptor gamma (PPARγ) in macrophages, 
enhanced the phosphatase and tensin homolog (PTEN) contents secreted 
in exosomes, which was subsequently used by recipient lung cancer cells 
[189]. Besides, the injection of apoptotic 344SQ cells blocked lung 
metastasis by increasing PPARγ/PTEN signaling in tumor cells and 
TAMs in-vivo. GW9662, a PPARγ antagonist, leads to reduced 
PPARγ/PTEN signaling, a reduction in EMT-activating transcription 
factors, including Snai1 and Zeb1, and reversed the anti-metastatic ef-
fect of apoptotic 344SQ injection [189]. Yoon et al. suggested that 
instilling ACs can inhibit bleomycin-mediated EMT in primary mice 
alveolar type II epithelial cells in-vivo [188]. Thus, the anti-EMT pro-
gramming of macrophages by ACs may supervise the gradual fibrotic 
reactions by generating potent paracrine EMT suppressors, such as 
curcumin [190]. 
2.3.15. Efferocytosis regulation by long-term exposure to inflammation in 
the tumor microenvironment 
The differences between acute and chronic conditions of inflamma-
tion in the TME have been characterized [191–193]. It was observed 
that chronic inflammation was a key factor in the tumorigenesis of 
several solid tumors [194,195] and that long-term exposure to acute 
inflammatory mediators leads to chronic inflammation [192]. The 
activation of DCs has a profound effect on adaptive immunity, although 
might be differentially impacted based on the duration of activation, as 
prolonged activation might exhaust immune cells. Long-term activated 
DC1s by LPS and IFNγ initiate apoptosis with IL-10 induction based on 
efferocytosis and TYRO3, Axl, and MerTK receptors. IL-12p70 and IL-10 
levels are positively associated with short-term activation and inversely 
associated with long-term activation. On the other hand, short-term 
stimulated CD1a+ DCs exhibit an increase in IL-12p70 expression, 
while long-term stimulated CD1a- DCs undergo apoptosis and secrete 
IL-10. The IFN-γ response is regulated by IL-12p70, as a significant 
decrease in IFN-γ was detected following blockage with an IL-12p70 
neutralizing antibody. Collectively, long-term activated DC1s change 
their profile toward tumor promotion and an anti-inflammatory 
phenotype [191]. 
Furthermore, micromolar concentrations of benzyl isothiocyanate- 
induced dying leukemic U937 cells liberate lower levels of IL-8 and 
monocyte chemoattractant protein-1, which might disrupt efferocytosis 
by macrophages in-vivo [196]. 
3. Conclusions and public health relevance 
Apoptotic cell clearance leads to the release of growth agents and the 
signaling activity of molecules that contribute to the maintenance of 
tissue homeostasis. Thus, to prevent the permeation of intracellular 
contents leading to inflammation and tissue damage, ACs are cleared 
from tissues by phagocytes. Moreover, efferocytosis leads to the toler-
ance of self-antigen immunity and, when defective, consequently con-
tributes to tissue damage and disease progression. One central feature of 
efferocytosis in wound healing is the production and release of cytokines 
through phagocytes that work to eliminate inflammation and promote 
tissue repair. Nevertheless, cytokines that contribute to immune inhi-
bition are also known to contribute to the TME, promoting tumor cell 
death and increasing the evasion of anti-tumor immunity. Conversely, 
conventional cancer therapies can also be involved in tumor progres-
sion, where the tumor cell debris produced as a result of chemotherapy 
may promote tumorigenesis by releasing pro-inflammatory cytokines. In 
this case, efferocytosis has an important role in the establishment of the 
TME and the expansion and metastasis of tumors. Therefore, since im-
mune mechanisms can lead to recurrence and metastasis of cancer, it is 
essential to use factors or pathways that increase efferocytosis but have 
minimal effect on anti-inflammatory cytokine expression. Understand-
ing the complexity of ATC signaling across viable tumor cells and 
phagocytic cells in the tumor context may be a major milestone in the 
improvement of tumor therapeutic results, as well as the inhibition of 
metastasis through the selection of host and ATC interactions. In addi-
tion, the majority of anticancer treatments stimulate malignant cell 
apoptosis. Consequently, it is necessary to have sufficient knowledge of 
efferocytosis and immune responses to discover novel modalities that 
limit cancer development and relapse. Future studies are warranted to 
determine the circumstances under which anti-tumor immunity is sup-
pressed or activated by therapy-generated cell debris. Collectively, it 
seems that the efferocytosis of ATCs can result in tumor development as 
well as metastasis by producing anti-inflammatory and, more impor-
tantly, tolerogenic cytokines in the TME. Therefore, it can be concluded 
that several ACs’s elements, such as anti-inflammatory mediators, 
growth factors, and cytokines are capable of providing suitable targets 
for anti-cancer therapy. 
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